{"type":"trials","record":{"id":37119,"source_id":"clinicaltrials-gov","external_id":"NCT01572025","title":"Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging","brief_summary":"* To test the hypothesis that supplementation of DHEA for at least twelve weeks prior to and during ovarian stimulation increases oocyte quantity (number of oocytes retrieved) and oocyte quality (clinical pregnancy rates and molecular markers) following IVF and IVF/ICSI treatment. * To evaluate the feasibility of conducting a large multicentre trial","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"University of Nottingham","enrollment":60,"countries":["United Kingdom"],"start_date":"2012-05-01","completion_date":"2014-12-01","last_update_date":"2015-12-09","source_url":"https://clinicaltrials.gov/study/NCT01572025","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:29.060472+00:00","last_seen_at":"2026-09-25T06:15:10.83+00:00","metadata":{"sex":"FEMALE","acronym":"DITTO","age_range":"23 Years to 48 Years","comparator":"Control","organization":"University of Nottingham","interventions":["Dehydroepiandrosterone","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of oocytes retrieved — within 15 weeks after DHEA/Placebo supplementation","Feasibility to conduct a large multicentre randomised controlled trial — with in 20 weeks of the research period (per p…","Oocyte quality (clinical and molecular markers) — The sample is collected at 14-16 weeks after recruitment and assessme…","Aneuploidy rates in the immature oocytes and unfertilized oocytes using microarray technology — The sample is collected…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Infertility","Ovarian Aging","Diminished Ovarian Reserve (DOR)","Predicted Poor-responders","Dehydroepiandrosterone","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: ovarian aging.","quality_checked_at":"2026-09-25T06:15:11.94354+00:00","duplicate_cluster_key":"id:nct01572025","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2012-05-01 to 2014-12-01","comparator":"Control","confidence":"structured-source","population":"FEMALE · 23 Years to 48 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:10.850Z","intervention":["Dehydroepiandrosterone","Placebo"],"participants":60,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of oocytes retrieved — within 15 weeks after DHEA/Placebo supplementation","Feasibility to conduct a large multicentre randomised controlled trial — with in 20 weeks of the research period (per p…","Oocyte quality (clinical and molecular markers) — The sample is collected at 14-16 weeks after recruitment and assessme…","Aneuploidy rates in the immature oocytes and unfertilized oocytes using microarray technology — The sample is collected…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"ovarian-aging","is_published":true,"match_reasons":["Title contains controlled term: ovarian aging.","Source terminology contains: ovarian aging, ovarian reserve.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Ovarian ageing","slug":"ovarian-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/37119","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}